9BSV

EBOV GP/Nanosota-EB2 complex

9BSV の概要

• エントリーDOI: 10.2210/pdb9bsv/pdb
• EMDBエントリー: 44873
• 分子名称: Nanosota-EB2, Envelope glycoprotein, alpha-D-mannopyranose-(1-4)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total)
• 機能のキーワード: ebov glycoprotein, nanobody, viral protein
• 由来する生物種: Vicugna pacos; 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 284319.01

構造登録者

Bu, F.,Ye, G.,Liu, B.,Li, F. (登録日: 2024-05-13, 公開日: 2024-12-18, 最終更新日: 2025-01-29)

主引用文献

Bu, F.,Ye, G.,Morsheimer, K.,Mendoza, A.,Turner-Hubbard, H.,Herbst, M.,Spiller, B.,Wadzinski, B.E.,Eaton, B.,Anantpadma, M.,Yang, G.,Liu, B.,Davey, R.,Li, F.
Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection.
Plos Pathog., 20:e1012817-e1012817, 2024

PubMed Abstract: The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and biochemical data revealed that Nanosota-EB1 binds to the glycan cap of GP1, preventing its protease cleavage, while Nanosota-EB2 binds to critical membrane-fusion elements in GP2, stabilizing it in the pre-fusion state. Nanosota-EB2 is a potent neutralizer of EBOV infection in vitro and offers excellent protection in a mouse model of EBOV challenge, while Nanosota-EB1 provides moderate neutralization and protection. Nanosota-EB1 and Nanosota-EB2 are the first nanobodies shown to inhibit authentic EBOV. Combined with our newly developed structure-guided in vitro evolution approach, they lay the foundation for nanobody-based therapies against EBOV and other viruses within the ebolavirus genus.

PubMed: 39715280
DOI: 10.1371/journal.ppat.1012817

実験手法

ELECTRON MICROSCOPY (3.1 Å)